Stockscreener 앱 받기
10.24
0.39%
0.04
시간 외 거래:
10.24
전일 마감가:
$10.20
열려 있는:
$10.22
하루 거래량:
728.53K
Relative Volume:
0.50
시가총액:
$997.27M
수익:
-
순이익/손실:
$-137.25M
주가수익비율:
-5.418
EPS:
-1.89
순현금흐름:
$-121.97M
1주 성능:
+2.81%
1개월 성능:
+11.91%
6개월 성능:
+7.56%
1년 성능:
+8.36%
1일 변동 폭
$10.04
$10.39
1주일 범위
$9.99
$11.08
52주 변동 폭
$3.8951
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.24 | 993.37M | 0 | -137.25M | -121.97M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC: Lead oncology programs progress to phase III with strong funding and promising early data - TradingView
Oric Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - Sahm
Biotech firm ORIC lines up three investor talks this February - Stock Titan
Oric Pharmaceuticals Approaches Critical Clinical Milestones - AD HOC NEWS
Price-Driven Insight from (ORIC) for Rule-Based Strategy - Stock Traders Daily
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Up 8.4%Here's What Happened - MarketBeat
J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating - 富途牛牛
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring 95% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 6.8%Time to Sell? - MarketBeat
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks - Baystreet.ca
Oric Pharmaceuticals (NASDAQ:ORIC) Sees Large Volume IncreaseWhat's Next? - MarketBeat
How Investors Are Reacting To ORIC Pharmaceuticals (ORIC) Big-Pharma Partnerships And Cancer Resistance Pipeline - Sahm
(ORIC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $25 - 富途牛牛
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: 74% Potential Upside Sparks Investor Interest - directorstalkinterviews.com
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oric Pharmaceuticals director Heyman sells shares worth $80,430 By Investing.com - Investing.com Australia
Oric Pharmaceuticals director Heyman sells shares worth $80,430 - Investing.com
ORIC Pharmaceuticals: Transition To Late-Stage Development Presents Upside - Seeking Alpha
Short Interest in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Grows By 19.6% - MarketBeat
ORIC Pharmaceuticals (ORIC) Is Up 32.5% After J&J Lung Cancer Collaboration and Pipeline UpdateWhat's Changed - Sahm
ORIC Pharmaceuticals Stock Pre-Market (-6.1%) : Form 144 Filings Signal Intent to Sell - Trefis
First Week of March 20th Options Trading For Oric Pharmaceuticals (ORIC) - Nasdaq
Volume Summary: Is ORIC Pharmaceuticals Inc forming higher highs and higher lows2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Is Roma Green Finance Limited gaining market shareJuly 2025 Trends & Free Community Consensus Stock Picks - baoquankhu1.vn
Assessing ORIC Pharmaceuticals (ORIC) Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration - Sahm
Why ORIC Pharmaceuticals (ORIC) Is Up 36.3% After New Cancer Data And Analyst Buzz - Yahoo Finance
H.C. Wainwright reiterates Buy rating on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
ORIC Pharmaceuticals provides 2025 operational highlights, upcoming milestones - MSN
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - marketscreener.com
ORIC: Advancing two late-stage oncology drugs with pivotal data and trials expected by 2027 - TradingView
Wedbush Reaffirms Outperform Rating for Oric Pharmaceuticals (NASDAQ:ORIC) - MarketBeat
Wedbush Reiterates Outperform Rating for ORIC at $20 | ORIC Stoc - GuruFocus
ORIC Pharmaceuticals reports progress on cancer drug candidates By Investing.com - Investing.com Nigeria
(ORIC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
ORIC Pharmaceuticals reports progress on cancer drug candidates - Investing.com
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones - Sahm
Oric Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Analysts at Piper Sandler - Defense World
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 7.8% HigherShould You Buy? - MarketBeat
Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: A Biotech Gem with 148% Upside Potential - DirectorsTalk Interviews
Oric Pharmaceuticals (NASDAQ:ORIC) Upgraded by Piper Sandler to Strong-Buy Rating - MarketBeat
Why ORIC Pharmaceuticals Inc. stock attracts global investors2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is ORIC Pharmaceuticals Inc. stock a buy before product launchesQuarterly Trade Report & Capital Efficient Trading Techniques - Улправда
Will ORIC Pharmaceuticals Inc. (4TZ) stock gain from green policiesEarnings Miss & Stock Timing and Entry Methods - Улправда
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Heyman Richard A. | Director |
Jan 16 '26 |
Sale |
12.00 |
3,200 |
38,415 |
213,072 |
1.24%
0.19%
자본화:
|
볼륨(24시간):